MYCN and neuroblastoma: The Children’s Oncology Group defines high-risk neuroblastomas using several established clinical indicators, including the International Neuroblastoma Risk Group Staging System, age at diagnosis, MYCN amplification status, International Neuroblastoma Pathology Classification, the presence or absence of segmental chromosomal aberrations, and ploidy [1].